Home Tags SGN-CD19A

Tag: SGN-CD19A

Denintuzumab Mafodotin: Testing Novel Regimens for Frontline and Relapsed DLBCL

Highlighted clinical data with denintuzumab mafodotin (SGN-CD19A; 19A; Seattle Genetics) in B-cell malignancies, including diffuse large B-cell lymphoma, also known as DLBCL, and B-lineage...

Phase II Trial of Denintuzumab Mafodotin Combination Therapy in Relapsed or...

A randomized phase II clinical trial of denintuzumab mafodotin, also known as SGN-CD19A (SGN-19A), in combination with the second-line salvage regimen of rituximab (Rituxan®;...

Multiple Data Presentations Support Seattle Genetics’ Antibody-Drug Conjugate Program Development Plans...

The 106th Annual Meeting of the American Association for Cancer Research (AACR) being held April 18-22, 2015 in Philadelphia, PA, included eight abstracts on...

SGN-CD19A Shows Encouraging Antitumor Activity in Recurrent Non-Hodgkin Lymphoma and...

Results from two ongoing phase I clinical trials evaluating SGN-CD19A (Seattle Genetics), an antibody-drug conjugate or ADC in development for the treatment of B-cell malignancies,...
Leukemia

Ongoing Phase I Clinical Trial of SGN-CD19A Demonstrates Encouraging Activity and...

Phase I interim data from a clinical trial with SGN-CD19A being developed for the treatment of B-cell malignancies, including acute lymphoblastic leukemia or ALL -- shows...